{"entity":{"id":"nct07562581","kind":"trial","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","aka":[],"tldr":"A phase 2 trial of Anlotinib in non-small-cell lung cancer, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., now recruiting.","summary":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC is a phase 2 interventional study registered as NCT07562581 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 48 participants planned, started 2026-06-15 and due to reach its primary completion in 2029-06. Interventions recorded: luvometinib + anlotinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07562581","url":"https://clinicaltrials.gov/study/NCT07562581"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["anlotinib"],"companies":["shanghai-fosun-pharmaceutical-industrial-development"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07562581","phase":"2","setting":"A Multicenter, Open-label, Single-arm Phase 2 Study to Evaluate the Efficacy and Safety of Luvometinib Combined With Anlotinib in Patients With KRAS-mutated Metastatic Non-small Cell Lung Cancer","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","enrolled":48,"outcomes":[]},"route":"/trials/nct07562581/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"}],"company":[{"id":"shanghai-fosun-pharmaceutical-industrial-development","kind":"company","name":"Shanghai Fosun Pharmaceutical Industrial Development","route":"/companies/shanghai-fosun-pharmaceutical-industrial-development/"}]}}